Form 4: Puma Biotechnology Director Allison Dorval Reports Stock Transactions

Director Allison Dorval reports acquisition of 27,000 shares of Puma Biotechnology stock and disposal of 60,000 shares.

Summary

• On June 18, 2024, Allison Dorval, a director of Puma Biotechnology, Inc., acquired 27,000 shares of common stock.
• The acquisition was made at a price of $0 per share.
• On the same day, Dorval disposed of 60,000 shares.
• Following these transactions, Dorval beneficially owns 60,000 shares of common stock.
• The 27,000 shares acquired represent Restricted Stock Units (RSUs) that vest in full on the earlier of the one-year anniversary of the grant date or the date of the annual shareholder meeting following the grant date, contingent upon continued service with the Issuer.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency to the market regarding the trading activities of company directors.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a company director, providing transparency into insider activity.

Key Dates